Caldan Therapeutics initial focus is on developing novel small molecule therapeutics that are activators of free fatty acid receptors implicated in metabolic diseases such as Type 2 Diabetes (T2D) and non-alcoholic steatohepatitis (NASH).
By drawing on its experience of GPCR targets, Caldan is focused on Research and Development programmes expected to address multiple aspects of T2D pathophysiology including insulin secretion, insulin sensitivity, islet cell protection, anti-inflammatory activity in muscle, liver and adipose tissue, weight loss, and decreased hepatic steatosis. This would be a step change in the treatment of T2D as it has the potential to deliver oral small molecules with the potential for glucose-lowering agents at least as good as currently marketed compounds but with additional benefits.
Caldan has exclusive commercial access to proprietary sensors developed at the University of Glasgow which will provide a considerable competitive edge in characterising compounds and tailoring them to the ideal profile. Caldan’s founders and management team has world-leading expertise in Free Fatty Acid (FFA) receptor pharmacology and medicinal chemistry combined with broad experience in GPCR drug discovery and development. Caldan Therapeutics is a private limited company supported by experienced international investors such as Epidarex Capital and the Scottish Investment Bank.